

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated Saturday, 29 June 2019 (the “**Prospectus**”) of IVD Medical Holding Limited (the “**Company**”) for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.*

Unless defined herein, terms used in this announcement shall have the same meanings as those defined in the Prospectus. This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or a solicitation of any offer to purchase or subscribe securities in the United States or elsewhere. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act or any state securities laws of the United States and may not be offered, sold, pledged or transferred within the United States or to, or for the account or benefit of U.S. persons, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirement of the U.S. Securities Act. There is not and it is not currently intended for there to be any public offering of the securities of the Company in the United States.

*In connection with the Global Offering, BOCI Asia Limited as the stabilising manager (the “**Stabilising Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may, to the extent permitted by applicable laws of Hong Kong or elsewhere, over-allocate or effect transactions with a view to stabilising or maintaining the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilising Manager, its affiliates or any person acting for it, to conduct any such stabilising action, which, if commenced, will be done at the sole and absolute discretion of the Stabilising Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilising activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilising action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Cap.571w), as amended, made under the SFO. The details of the intended stabilisation and how it will be regulated under the SFO are set forth in the section headed “Structure and Conditions of the Global Offering” in the Prospectus.*

Potential investors should be aware that stabilising action cannot be taken to support the price of the Shares for longer than the stabilisation period which begins on the Listing Date and is expected to expire on Sunday, 4 August 2019, being the 30th day after the last date for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilising action may be taken, and demand for the Shares, and therefore the price of the Shares, could fall.

The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to the terms and conditions as set out in the Prospectus and the related Application Forms.



IVD Medical Holding Limited

華檢醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 333,400,000 Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	: 33,340,000 Shares (subject to adjustment)
Number of International Offer Shares	: 300,060,000 Shares (subject to adjustment and the Over-allotment Option)
Maximum Offer Price	: HK\$3.68 per Offer Share, plus brokerage fee of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)
Nominal value	: US\$0.0005 per Share
Stock code	: 1931

Sole Sponsor and Sole Global Coordinator



Joint Bookrunners and Joint Lead Managers



Application has been made by the Company to the Listing Committee of the Stock Exchange for the granting of the listing of, and permission to deal in, the Shares in issue and to be issued and sold as described in the Prospectus (including Shares to be issued pursuant to the Capitalisation Issue, Shares which may fall to be issued or sold upon the exercise of the Over-allotment Option and the options granted or to be granted under the ESOP or the Share Option Scheme). Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Friday, 12 July 2019, it is expected that dealings in the Shares on the Stock Exchange will commence at 9:00 a.m. on Friday, 12 July 2019.

The Global Offering comprises the Hong Kong Public Offering of initially 33,340,000 Shares (subject to adjustment) and the International Offering of initially 300,060,000 Shares (subject to adjustment and the Over-allotment Option), representing 10% and 90% of the total number of Offer Shares initially being offered under the Global Offering, respectively. The allocation of the Shares between the Hong Kong Public Offering and the International Offering is subject to reallocation as stated in the section headed “Structure and Conditions of the Global Offering – The Hong Kong Public Offering” in the Prospectus. In particular, the Sole Global Coordinator may reallocate the Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to Practice Note 18 of the Listing Rules, the maximum total number of Offer Shares that may be reallocated to the Hong Kong Public Offering following such reallocation shall be not more than double the initial allocation to the Hong Kong Public Offering (i.e. 66,680,000 Shares), and the final Offer Price shall be fixed at the bottom end of the indicative Offer Price range (i.e. HK\$3.07 per Offer Price).

In connection with the Global Offering, the Company and NHPE are expected to grant the Over-allotment Option to the International Underwriter(s), which is exercisable by the Sole Global Coordinator on behalf of the International Underwriter(s) at any time from the date of the International Underwriting Agreement until 30 days from the last day for the lodging of applications under the Hong Kong Public Offering, to require the Company and NHPE to allot, issue or sell up to 50,010,000 additional Shares (for which our Company may be required to allot and issue up to 30,010,000 Shares and NHPE may be required to sell up to 20,000,000 Shares), representing 15% of the total number of Offer Shares initially available under the Global Offering, solely to cover over-allocations in the International Offering, if any, subject to the same terms and conditions as the other Offer Shares. In the event that the Over-allotment Option is exercised, an announcement will be made by the Company on the website of the Stock Exchange at www.hkexnews.hk and the website of the Company at www.ivdholding.com.

Subject to the granting of the approval for listing of, and permission to deal in, the Shares on the Stock Exchange and compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the Listing Date or such other date as may be determined by HKSCC. Settlement of transactions between Exchange Participants (as defined in the Listing Rules) is required to take place in CCASS on the second Business Day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made to enable the Shares to be admitted into CCASS.

The Offer Price will not be more than HK\$3.68 per Offer Share and is currently expected to be not less than HK\$3.07 per Offer Share, unless otherwise announced. Applicants for the Hong Kong Offer Shares are required to pay, on application, the maximum Offer Price of HK\$3.68 per Offer Share plus the brokerage fee of 1%, SFC transaction levy of 0.0027% and the Stock Exchange trading fee of 0.005% payable on each Offer Share, subject to refund if the Offer Price as finally determined is less than HK\$3.68 per Offer Share.

If an application is rejected, not accepted or accepted in part only, or if the Offer Price as finally determined is less than the maximum offer price of HK\$3.68 per Offer Share (excluding brokerage, SFC transaction levy and the Stock Exchange trading fee thereon), or if the conditions of the Hong Kong Public Offering as set out in the section headed “Structure and Conditions of the Global Offering – Conditions of the Hong Kong Public Offering” in the Prospectus or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy and the Stock Exchange trading fee, will be refunded, without interest or the cheque or banker’s cashier order will not be cleared. Any refund of your application monies will be made on or before 11 July 2019.

Applications for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus and the Application Forms and the designated website (www.hkeipo.hk) for the HK eIPO White Form. Applicants who would like to be allotted Hong Kong Offer Shares in their own names should (i) complete and sign the **WHITE** Application Forms or (ii) submit applications online through the designated website of the **HK eIPO White Form** Service Provider at www.hkeipo.hk. Applicants who would like to have the allotted Hong Kong Offer Shares issued in the name of HKSCC Nominees and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants maintained in CCASS should either (i) complete and sign the **YELLOW** Application Forms or (ii) give electronic application instructions to HKSCC via CCASS to cause HKSCC Nominees to apply for you.

Copies of the Prospectus, together with the **WHITE** Application Form, may be obtained during normal business hours from 9:00 a.m. on Saturday, 29 June 2019 until 12:00 noon on Friday, 5 July 2019 from:

1. any of the following address of the Hong Kong Underwriter(s):

BOCI Asia Limited

26th Floor, Bank of China Tower
1 Garden Road
Central
Hong Kong

AMTD Global Markets Limited

23/F – 25/F, Nexxus Building
41 Connaught Road Central
Hong Kong

China Industrial Securities International Capital Limited

7/F, Three Exchange Square
8 Connaught Place
Central
Hong Kong

Haitong International Securities Company Limited

22/F, Li Po Chun Chambers
189 Des Voeux Road Central
Hong Kong

2. any of the following designated branches of Bank of China (Hong Kong) Limited:

District	Branch Name	Address
Hong Kong Island	Causeway Bay Branch	505 Hennessy Road, Causeway Bay, Hong Kong
Kowloon	Mei Foo Mount Sterling Mall Branch	Shop N47-49, G/F, Mount Sterling Mall, Mei Foo Sun Chuen, Kowloon
	Olympian City Branch	Shop 133, 1/F, Olympian City 2, 18 Hoi Ting Road, Kowloon
New Territories	City One Sha Tin Branch	Shop Nos.24-25, G/F, Fortune City One Plus, No.2 Ngan Shing Street, Sha Tin, New Territories
	Tuen Mun San Hui Branch	G13-G14 Eldo Court, Heung Sze Wui Road, Tuen Mun, New Territories
	Kwai Chung Plaza Branch	A18-20, G/F Kwai Chung Plaza, 7-11 Kwai Foo Road, Kwai Chung, New Territories

Copies of the Prospectus, together with the **YELLOW** Application Form, may be obtained during normal business hours from 9:00 a.m. on Saturday, 29 June 2019 until 12:00 noon on Friday, 5 July 2019 at the Depository Counter of HKSCC at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong or from your stockbroker, who may have such **YELLOW** Application Forms and the Prospectus available.

The **WHITE** or **YELLOW** Application Forms completed in accordance with the instructions printed thereon, together with a cheque or banker's cashier order attached and marked payable to "**BANK OF CHINA (HONG KONG) NOMINEES LIMITED – IVD MEDICAL HOLDING PUBLIC OFFER**" for the payment, should be securely stapled and deposited in the special collection boxes provided at any of the designated branches of the receiving bank referred to above on such dates and during such time as specified in the Application Forms.

Saturday, 29 June 2019 – 9:00 a.m. to 1:00 p.m.
Tuesday, 2 July 2019 – 9:00 a.m. to 5:00 p.m.
Wednesday, 3 July 2019 – 9:00 a.m. to 5:00 p.m.
Thursday, 4 July 2019 – 9:00 a.m. to 5:00 p.m.
Friday, 5 July 2019 – 9:00 a.m. to 12:00 noon

Applicants applying under the **HK eIPO White Form** may submit applications through the designated website at www.hkeipo.hk (24 hours daily, except on the last application day) from 9:00 a.m. on Saturday, 29 June 2019 until 11:30 a.m. on Friday, 5 July 2019 and the latest time for completing full payment of application monies in respect of such applications will be 12:00 noon on Friday, 5 July 2019 or such later time as described in the section headed "How to Apply for Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening of the Application Lists" in the Prospectus.

CCASS Clearing/Custodian Participants can input electronic application instructions at the following times on the following dates:⁽¹⁾

Saturday, 29 June 2019 – 9:00 a.m. to 1:00 p.m.
Tuesday, 2 July 2019 – 8:00 a.m. to 8:30 p.m.
Wednesday, 3 July 2019 – 8:00 a.m. to 8:30 p.m.
Thursday, 4 July 2019 – 8:00 a.m. to 8:30 p.m.
Friday, 5 July 2019 – 8:00 a.m. to 12:00 noon

Note:

(1) These times are subject to change as HKSCC may determine from time to time with prior notification to CCASS Clearing/Custodian Participants.

CCASS Investor Participants can input **electronic application instructions** from 9:00 a.m. on Saturday, 29 June, 2019 until 12:00 noon on Friday, 5 July 2019 (24 hours daily, except on the last application day) or such later time as described in the section headed “How to Apply for Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening of the Application Lists” in the Prospectus.

Please refer to the sections headed “Structure and Conditions of the Global Offering” and “How to Apply for Hong Kong Offer Shares” in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

The Company expects to announce the final Offer Price, the level of indication of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on Thursday, 11 July 2019 (i) in the South China Morning Post (in English); (ii) in the Hong Kong Economic Times (in Chinese); (iii) on the website of the Company at www.ivdholding.com; and (iv) on the website of the Stock Exchange at www.hkexnews.hk. The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offering will be made available through a variety of channels, at the times and date and in the manner specified in the section headed “How to Apply for Hong Kong Offer Shares – 11. Publication of Results” in the Prospectus.

The Company will not issue temporary documents of title or receipt for application fees received. Share certificates will only become valid provided that the Global Offering has become unconditional in all respects and the right of termination described in the section headed “Underwriting – Underwriting arrangements and expenses – Hong Kong Public Offering – Grounds for termination” in the Prospectus has not been exercised, which is expected to be at 8:00 a.m. on Friday, 12 July 2019.

Dealings in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Friday, 12 July 2019. The Shares will be traded in board lots of 1,000 Shares each. The stock code of the Shares is 1931.

By order of the Board
IVD Medical Holding Limited
Mr. Ho Kuk Sing
Chairman and Executive Director

Hong Kong, Saturday, 29 June 2019

As at the date of this announcement, the Board comprises Mr. Ho Kuk Sing, Mr. Leung King Sun and Mr. Lin Xianya, as executive Directors; Mr. Chen Xingang, Mr. Yang Zhaoxu and Mr. Chan Kwok King, Kingsley, as non-executive Directors; and Mr. Lau Siu Ki, Mr. Zhong Renqian, and Mr. Leung Ka Sing, as independent non-executive Directors.